JP2015501784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501784A5 JP2015501784A5 JP2014540115A JP2014540115A JP2015501784A5 JP 2015501784 A5 JP2015501784 A5 JP 2015501784A5 JP 2014540115 A JP2014540115 A JP 2014540115A JP 2014540115 A JP2014540115 A JP 2014540115A JP 2015501784 A5 JP2015501784 A5 JP 2015501784A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- methyl
- cycloalkyl
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)[n]1c2cc(Br)cc(C(NCc3c(C)cc(*)nc3OC)=O)c2c(C)c1 Chemical compound CC(C)[n]1c2cc(Br)cc(C(NCc3c(C)cc(*)nc3OC)=O)c2c(C)c1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555650P | 2011-11-04 | 2011-11-04 | |
| US61/555,650 | 2011-11-04 | ||
| PCT/US2012/063235 WO2013067296A1 (en) | 2011-11-04 | 2012-11-02 | Method of treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501784A JP2015501784A (ja) | 2015-01-19 |
| JP2015501784A5 true JP2015501784A5 (OSRAM) | 2015-12-24 |
| JP6005753B2 JP6005753B2 (ja) | 2016-10-12 |
Family
ID=48192800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540115A Expired - Fee Related JP6005753B2 (ja) | 2011-11-04 | 2012-11-02 | 治療の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9242962B2 (OSRAM) |
| EP (1) | EP2773754B1 (OSRAM) |
| JP (1) | JP6005753B2 (OSRAM) |
| KR (1) | KR20140095073A (OSRAM) |
| CN (1) | CN104039956A (OSRAM) |
| AU (1) | AU2012332297B2 (OSRAM) |
| BR (1) | BR112014010803A2 (OSRAM) |
| CA (1) | CA2854447A1 (OSRAM) |
| ES (1) | ES2600161T3 (OSRAM) |
| RU (1) | RU2621148C2 (OSRAM) |
| WO (1) | WO2013067296A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2015077194A1 (en) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| US20160340674A1 (en) * | 2014-02-10 | 2016-11-24 | University Of Rochester | Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases |
| WO2015132765A1 (en) * | 2014-03-07 | 2015-09-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| LT3121175T (lt) * | 2014-03-17 | 2020-03-10 | Daiichi Sankyo Company, Limited | 1,3-benzodioksazolo dariniai, kaip ezh1 ir (arba) ezh2 inhibitoriai |
| MA40848A (fr) * | 2014-10-28 | 2021-05-05 | Glaxosmithkline Ip No 2 Ltd | Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) |
| WO2016073903A1 (en) * | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Use of compositions modulating chromatin structure for graft versus host disease (gvhd) |
| WO2016073956A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| CN108136011A (zh) * | 2015-08-03 | 2018-06-08 | 星座制药公司 | Ezh2抑制剂和调节性t细胞功能的调制 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| CN105541801B (zh) * | 2016-01-18 | 2018-07-17 | 常州大学 | Ezh2甲基转移酶抑制剂gsk126的合成方法 |
| CN109069508A (zh) | 2016-04-22 | 2018-12-21 | 达纳-法伯癌症研究所股份有限公司 | Ezh2抑制剂及其用途 |
| EP3472166A1 (en) * | 2016-06-20 | 2019-04-24 | Novartis AG | Imidazopyrimidine compounds useful for the treatment of cancer |
| JP6816287B2 (ja) * | 2016-09-07 | 2021-01-20 | シャンハイ ハイヘ ファーマシューティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｈｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ | ピリジン並びに５員芳香環系化合物、その製造方法及び使用 |
| WO2018075598A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| US11214561B2 (en) | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| TWI837231B (zh) | 2018-11-29 | 2024-04-01 | 日商第一三共股份有限公司 | 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途 |
| AU2019409868A1 (en) * | 2018-12-21 | 2021-07-08 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating inflammation |
| CN109761960B (zh) * | 2019-02-25 | 2021-08-31 | 江苏豪森药业集团有限公司 | 抗耐药抗肿瘤egfr抑制剂的制备方法 |
| CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| WO2021021986A1 (en) | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of cd38 |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| PH12022551578A1 (en) * | 2019-12-25 | 2023-11-29 | Nippon Shinyaku Co Ltd | Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome |
| AU2022212035A1 (en) | 2021-01-29 | 2023-08-03 | Boehringer Ingelheim International Gmbh | Quinolines and azaquinolines as inhibitors of cd38 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2584713B1 (fr) | 1985-07-11 | 1988-09-09 | Roussel Uclaf | Nouveaux derives de l'indole carboxamide, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant |
| DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| WO2004112719A2 (en) | 2003-06-19 | 2004-12-29 | Smithkline Beecham Corporation | Chemical compounds |
| US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| JP4861976B2 (ja) * | 2004-03-11 | 2012-01-25 | アクテリオン ファーマシューティカルズ リミテッド | インドール−１−イル酢酸誘導体 |
| WO2007053114A1 (en) * | 2005-10-31 | 2007-05-10 | S*Bio Pte Ltd | Method of predicting a response to hdac inhibitors |
| WO2008109534A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof |
| WO2009006577A2 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| WO2009048958A2 (en) * | 2007-10-08 | 2009-04-16 | The Board Of Regents Of The University Of Texas System | Methods and compositions involving chitosan nanoparticles |
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| US20110237606A1 (en) | 2008-09-26 | 2011-09-29 | Agency Of Science, Technology And Research | 3-Deazaneplanocin Derivatives |
| US9107942B2 (en) * | 2008-10-31 | 2015-08-18 | University Of Rochester | Methods of diagnosing and treating fibrosis |
| KR20120046099A (ko) * | 2009-02-04 | 2012-05-09 | 유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 | 섬유화를 억제하고 섬유화 질병을 치료하는 방법 |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| EP2566327B1 (en) * | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| JP2014511389A (ja) * | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換６，５−縮合二環式ヘテロアリール化合物 |
-
2012
- 2012-11-02 KR KR1020147014677A patent/KR20140095073A/ko not_active Withdrawn
- 2012-11-02 AU AU2012332297A patent/AU2012332297B2/en not_active Ceased
- 2012-11-02 WO PCT/US2012/063235 patent/WO2013067296A1/en not_active Ceased
- 2012-11-02 BR BR112014010803A patent/BR112014010803A2/pt not_active IP Right Cessation
- 2012-11-02 EP EP12845460.0A patent/EP2773754B1/en active Active
- 2012-11-02 US US14/355,964 patent/US9242962B2/en not_active Expired - Fee Related
- 2012-11-02 JP JP2014540115A patent/JP6005753B2/ja not_active Expired - Fee Related
- 2012-11-02 ES ES12845460.0T patent/ES2600161T3/es active Active
- 2012-11-02 RU RU2014122546A patent/RU2621148C2/ru not_active IP Right Cessation
- 2012-11-02 CA CA2854447A patent/CA2854447A1/en not_active Abandoned
- 2012-11-02 CN CN201280066115.XA patent/CN104039956A/zh active Pending
-
2015
- 2015-11-30 US US14/953,546 patent/US9446041B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501784A5 (OSRAM) | ||
| EP2549875B1 (en) | Soluble guanylate cyclase activators | |
| JP6215338B2 (ja) | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 | |
| EP2789615B1 (en) | Azaindazoles as Btk kinase modulators and use thereof | |
| CA2934137C (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
| US10428044B2 (en) | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | |
| AU2014373735B2 (en) | Therapeutic inhibitory compounds | |
| AU2005259894C1 (en) | Pyrrolotriazine kinase inhibitors | |
| EP2566477B1 (en) | Amino-quinolines as kinase inhibitors | |
| CN113454082B (zh) | 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途 | |
| WO2016011390A1 (en) | Irak4 inhibiting agents | |
| CA2803842A1 (en) | Nicotinamide derivative or salt thereof as syk-inhibitors | |
| HK1217482A1 (en) | Enzyme modulators and therapies | |
| EP3568390A1 (en) | Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof | |
| JP2013528591A5 (OSRAM) | ||
| WO2009027283A1 (en) | Triazolopyridine compounds and their use as ask inhibitors | |
| CN103702979A (zh) | 含亚磺酰亚胺基团的4-芳基-n-苯基-1,3,5-三嗪-2-胺 | |
| MX2015004151A (es) | Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8). | |
| JP2009517383A (ja) | 新規な３−ビシクロカルボニルアミノピリジン−２−カルボキサミド又は３−ビシクロカルボニルアミノピラジン−２−カルボキサミド | |
| WO2013067300A1 (en) | Method of treatment | |
| AU2005300736B2 (en) | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors | |
| KR20150135794A (ko) | 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도 | |
| KR20170044204A (ko) | 오렉신―１ 수용체의 억제제로서의 치료 화합물 | |
| AU2014347026A1 (en) | Substituted pyridine derivatives useful as GSK-3 inhibitors | |
| MX2010013549A (es) | Imidazoles sustituidos con 2-piridilo, como inhibidores de alk4 y/o alk4. |